cv8102
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02238756)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lyssavirus rabiesImmunity, active
Lyssavirus rabies immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cv8102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03291002 | Phase 1 | Sep 25, 2017 | CureVac AG |
| NCT03203005 | Phase 1/Phase 2 (Phase 2) | Sep 18, 2017 | CureVac AG, European Commission, Fondazione Giovanni Pascale, immatics Biotechnologies GmbH |
| NCT02238756 | Phase 1 | Sep 1, 2014 | CureVac AG |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CureVac AG | For profit | 3 | 2 | 2 | 2014 |
| European Commission | Government | 1 | 0 | 1 | 2017 |
| Fondazione Giovanni Pascale | Academic/Hospital | 1 | 1 | 1 | 2017 |
| immatics Biotechnologies GmbH | For profit | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1